Brown Advisory Inc. Purchases Shares of 35,538 BioCardia, Inc. (NASDAQ:BCDA)

Brown Advisory Inc. purchased a new stake in BioCardia, Inc. (NASDAQ:BCDA) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 35,538 shares of the company’s stock, valued at approximately $90,000. Brown Advisory Inc. owned 0.76% of BioCardia as of its most recent filing with the Securities & Exchange Commission.

Separately, Geode Capital Management LLC lifted its stake in BioCardia by 110.3% in the fourth quarter. Geode Capital Management LLC now owns 30,987 shares of the company’s stock valued at $68,000 after buying an additional 16,251 shares during the period. Institutional investors own 20.57% of the company’s stock.

Insider Buying and Selling

In related news, CEO Peter Altman purchased 24,096 shares of the firm’s stock in a transaction that occurred on Monday, June 30th. The stock was acquired at an average price of $2.08 per share, for a total transaction of $50,119.68. Following the completion of the acquisition, the chief executive officer owned 165,862 shares of the company’s stock, valued at $344,992.96. This represents a 17.00% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Andrew Scott Blank purchased 72,289 shares of the firm’s stock in a transaction that occurred on Monday, June 30th. The shares were bought at an average price of $2.08 per share, with a total value of $150,361.12. Following the acquisition, the director directly owned 346,023 shares of the company’s stock, valued at $719,727.84. This represents a 26.41% increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 215,662 shares of company stock worth $441,960. 20.00% of the stock is owned by corporate insiders.

BioCardia Stock Performance

Shares of BCDA opened at $2.26 on Thursday. BioCardia, Inc. has a 52-week low of $1.63 and a 52-week high of $4.66. The business’s 50 day moving average price is $2.23 and its two-hundred day moving average price is $2.30. The firm has a market cap of $12.43 million, a PE ratio of -0.97 and a beta of 0.81.

BioCardia (NASDAQ:BCDA) last issued its earnings results on Wednesday, May 14th. The company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.20). Research analysts predict that BioCardia, Inc. will post -3.52 EPS for the current fiscal year.

BioCardia Company Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.